share_log

Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $49

Benzinga ·  Sep 11, 2023 09:52

Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $46 to $49.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment